Parkinson’s Disease: Low-Dose Haloperidol Increases Dopamine Receptor Sensitivity and Clinical Response

Table 1

Patient data.

Subject	Age	M/F	Disease duration, years	SCOPA baseline at week 1	Medication	L-DOPA dose/day
101	70	M	1	14	Sinemet 100/25, 3/day	300 mg
102	59	F	2	25	Levocarb 100/25, 1 qhs prn; Stalevo 150/37.5; 5/day	850 mg
103	81	F	31	42	Sinemet cr 100/25, 5/day; Sinemet 100, 1/day	600 mg
104	80	M	9	26	Levocarb 100/10 2 tabs, 5/day	1000 mg
105	76	M	10	23	Pramipexole 200 mg, 3/day	=600 mg
106	70	M	12	29	Apo-Levocarb 100/25, 3 tabs, 4/day	1200 mg
107	81	M	4	20	Apo-Levocarb 25 mg, 3/day	300 mg
108	65	M	10	27	None	0 mg
109	61	M	3	16	Levocarb 25 mg, 4/day	100 mg
110	67	M	8	16	Levocarb 250/25 mg, 4/day; pramipexole 1 mg/day	1000 mg
112	72	M	6	30	Apo-Levocarb 25 mg, 4/day	100 mg
113	61	M	6	21	Sinemet, 100/25, 3/day	300 mg
114	63	M	12	28	Sinemet 100/25, 2 tabs, 5/day	1000 mg
115	77	F	7	30	Sinemet 100/25	700 mg
117	92	M	15	13	Sinemet cr 100/50, 2/day	200 mg
118	80	M	5	17	Apo-Levocarb 100/25, 1/day	100 mg
Average	72		8.8	23.6
s.e.				1.9